In this article, Christian Fortunel, Vice President of LZ Lifescience, discusses today’s most significant market trends, including continuous manufacturing, the increased demand for individualised medicines, patient-centricity and globalisation, as well as FDA’s focus on quality, and addresses the advantages that manufacturing execution systems (MES) bring in meeting the complexities of these developments.
Pharmaceutical trends and the role of MES
With trends in the pharmaceutical industry continuously evolving, manufacturers are under increasing pressure to keep pace and adapt their operations to meet changing needs
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Read moreTitan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Trending Articles
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Manufacturing
What makes a GMP quality system effective in day-to-day pharmaceutical manufacturing?
Your quality system may have a procedure for almost everything: reporting a deviation, reviewing a batch record, changing equipment settings and training the people who operate it. But having a procedure and getting a useful answer from it are two different things
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.